Technology chemokine to increase the efficacy of tissue-specific stem cells homing relief
Tuesday, April 13, 2010
Werewolf Fingerboards
Entest Biomedical Inc. (OTCBB: ENTB) announced the filing of a patent application on the use of stem cells to attract molecules called chemokines in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other conditions that may benefit from increased stem cell homing.
Chemokines are produced naturally by the body in times of tissue injury and believed to be an essential part of the healing process. Entest intellectual property used these molecules to attract stem cells to damaged tissue to increase the effectiveness of existing and developing new cell therapies.
"Clinical trials of stem cell have demonstrated safety and efficacy in the signs of heart failure, liver failure and peripheral arterial disease. Unfortunately there is still much room for improvement in patient outcomes," said Dr. Steven Josephs, lead inventor of the patent application. "The present invention provides a way to make stem cell therapy work better, increasing the number of stem cells in the tissue where they are needed. "
The FDA has already approved a drug that works by altering the homing of stem cells. Mozobil, a drug developed by Genzyme Corporation, is used to induce stem cells to make a specific anatomic (bone marrow). The methods included in the function of a patent application Entest opposite way using specific molecules attract stem cells.
"Today's presentation represents the global strategy Entest patent to deal with COPD through a multidisciplinary way, "said David Koos, Chairman and CEO of Entest. "Since some of these technologies may be useful in increasing stem cell therapy for other indications, we are always looking for partnerships for development in our non-core areas."
Chemokines are produced naturally by the body in times of tissue injury and believed to be an essential part of the healing process. Entest intellectual property used these molecules to attract stem cells to damaged tissue to increase the effectiveness of existing and developing new cell therapies.
"Clinical trials of stem cell have demonstrated safety and efficacy in the signs of heart failure, liver failure and peripheral arterial disease. Unfortunately there is still much room for improvement in patient outcomes," said Dr. Steven Josephs, lead inventor of the patent application. "The present invention provides a way to make stem cell therapy work better, increasing the number of stem cells in the tissue where they are needed. "
The FDA has already approved a drug that works by altering the homing of stem cells. Mozobil, a drug developed by Genzyme Corporation, is used to induce stem cells to make a specific anatomic (bone marrow). The methods included in the function of a patent application Entest opposite way using specific molecules attract stem cells.
"Today's presentation represents the global strategy Entest patent to deal with COPD through a multidisciplinary way, "said David Koos, Chairman and CEO of Entest. "Since some of these technologies may be useful in increasing stem cell therapy for other indications, we are always looking for partnerships for development in our non-core areas."
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment